Literature DB >> 11371570

G protein-coupled receptors desensitize and down-regulate epidermal growth factor receptors in renal mesangial cells.

J S Grewal1, L M Luttrell, J R Raymond.   

Abstract

Different types of plasma membrane receptors engage in various forms of cross-talk. We used cultures of rat renal mesangial cells to study the regulation of EGF receptors (EGFRs) by various endogenous G protein-coupled receptors (GPCRs). GPCRs (5-hydroxytryptamine(2A), lysophosphatidic acid, angiotensin AT(1), bradykinin B(2)) were shown to transactivate EGFRs through a protein kinase C-dependent pathway. This transactivation resulted in the initiation of multiple cellular signals (phosphorylation of the EGFRs and ERK and activation of cAMP-responsive element-binding protein (CREB), NF-kappaB, and E2F), as well as subsequent rapid down-regulation of cell-surface EGFRs and internalization and desensitization of the EGFRs without change in the total cellular complement of EGFRs. Internalization of the EGFRs and the down-regulation of cell-surface receptors in mesangial cells were blocked by pharmacological inhibitors of clathrin-mediated endocytosis and in HEK293 cells by transfection of cDNA constructs that encode dominant negative beta-arrestin-1 or dynamin. Whereas all of the effects of GPCRs on EGFRs were dependent to a great extent on protein kinase C, those initiated by EGF were not. These studies demonstrate that GPCRs can induce multiple signals through protein kinase C-dependent transactivation of EGFRs. Moreover, GPCRs induce profound desensitization of EGFRs by a process associated with the loss of cell-surface EGFRs through clathrin-mediated endocytosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371570     DOI: 10.1074/jbc.M103578200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Reviews in molecular biology and biotechnology: transmembrane signaling by G protein-coupled receptors.

Authors:  Louis M Luttrell
Journal:  Mol Biotechnol       Date:  2008-02-01       Impact factor: 2.695

2.  Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion.

Authors:  X Wu; T Kihara; H Hongo; A Akaike; T Niidome; H Sugimoto
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

3.  Down-regulation of c-Cbl by morphine accounts for persistent ERK1/2 signaling in delta-opioid receptor-expressing HEK293 cells.

Authors:  Daniela A Eisinger; Hermann Ammer
Journal:  J Biol Chem       Date:  2009-10-14       Impact factor: 5.157

4.  A differential role for endocytosis in receptor-mediated activation of Nox1.

Authors:  Francis J Miller; Xi Chu; Bojana Stanic; Xin Tian; Ram V Sharma; Robin L Davisson; Fred S Lamb
Journal:  Antioxid Redox Signal       Date:  2010-03-01       Impact factor: 8.401

5.  Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells.

Authors:  Derick Mitchell; Karen Rodgers; Jennifer Hanly; Blaithin McMahon; Hugh R Brady; Finian Martin; Catherine Godson
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

6.  Quantitative changes in intracellular calcium and extracellular-regulated kinase activation measured in parallel in CHO cells stably expressing serotonin (5-HT) 5-HT2A or 5-HT2C receptors.

Authors:  Patricia K Seitz; Nicole M Bremer; Andrew G McGinnis; Kathryn A Cunningham; Cheryl S Watson
Journal:  BMC Neurosci       Date:  2012-03-07       Impact factor: 3.288

Review 7.  Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease.

Authors:  Yu Yang; Hui Huang; Zheng Xu; Jun-Kai Duan
Journal:  J Diabetes Res       Date:  2017-08-08       Impact factor: 4.011

8.  Sustained activation of protein kinase C induces delayed phosphorylation and regulates the fate of epidermal growth factor receptor.

Authors:  Mengling Liu; Jolanta Idkowiak-Baldys; Patrick L Roddy; Aleksander Baldys; John Raymond; Christopher J Clarke; Yusuf A Hannun
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.